Vutrisiran Alternatives Compared
Vutrisiran | Amvuttra (vutrisiran) | Tafamidis |
|
---|
Vutrisiran | Amvuttra (vutrisiran) | Tafamidis |
|
---|---|---|---|
Prescription only
Prescribed for Hereditary Amyloidosis, Cardiomyopathy of Transthyretin-Mediated Amyloidosis, Transthyretin-Related Amyloidosis. Vutrisiran may also be used for purposes not listed in this medication guide. View more |
Prescription only
Prescribed for Hereditary Amyloidosis, Cardiomyopathy of Transthyretin-Mediated Amyloidosis, Transthyretin-Related Amyloidosis. Amvuttra may also be used for purposes not listed in this medication guide. View more |
Prescription only
Prescribed for Cardiomyopathy of Transthyretin-Mediated Amyloidosis, Hereditary Amyloidosis, Transthyretin-Related Amyloidosis. Tafamidis may also be used for purposes not listed in this medication guide. View more |
|
More about Vutrisiran | More about Amvuttra (vutrisiran) | More about Tafamidis | |
Ratings & Reviews | |||
Vutrisiran has an average rating of 5.0 out of 10 from a total of 1 ratings on Drugs.com. 0% of reviewers reported a positive effect, while 0% reported a negative effect. |
Amvuttra has an average rating of 5.0 out of 10 from a total of 1 ratings on Drugs.com. 0% of reviewers reported a positive effect, while 0% reported a negative effect. |
Tafamidis has an average rating of 7.7 out of 10 from a total of 15 ratings on Drugs.com. 47% of reviewers reported a positive effect, while 0% reported a negative effect. |
|
Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||
View all Vutrisiran side effects |
View all Amvuttra side effects |
View all Tafamidis side effects |
|
Drug Class | |||
Generic Availability | |||
N/A |
N/A |
||
Pricing and Coupons * Prices are without insurance | |||
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
|
Dosage Forms | |||
N/A |
|
N/A |
|
Brand Names | |||
Amvuttra |
N/A |
Vyndamax, Vyndaqel | |
Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||
5.2 hours |
5.2 hours |
59 hours |
|
CSA Schedule 1 View glossary of CSA terms | |||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
|
Pregnancy Category | |||
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
Summary unavailable. See the full pregnancy warnings document. |
|
Drug Interactions | |||
No known drug interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known drug interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
A total of 32 drugs are known to interact with Tafamidis:
|
|
Alcohol/Food/Lifestyle Interactions | |||
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
|
Disease Interactions | |||
First Approval Date | |||
June 13, 2022 |
June 13, 2022 |
May 03, 2019 |
|
WADA Class View classifications | |||
N/A |
N/A |
N/A |
|
More Information | |||
Patient Resources | |||
Professional Resources | |||
Related Treatment Guide | |||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.